Vimarsana
Biggest News Aggregation in the World

Page 7 - Alligator Bioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Alligator Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Alligator Bioscience Today - Breaking & Trending Today

Alligator Bioscience Announces Commencement of a Sponsored Research Agreement with the University of Pennsylvania Led by Dr. Gregory Beatty - Vimarsana News

Alligator Bioscience Announces Commencement of a Sponsored Research Agreement with the University of Pennsylvania Led by Dr. Gregory Beatty

LUND, Sweden, Jan. 19, 2022 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the initiation a sponsored research collaboration to study biomarker data from Alligator's

Alligator Bioscience Announces OPTIMIZE-1 Trial Update: Cohort Fully Dosed with No Adverse Effects Reported - Vimarsana News

Alligator Bioscience Announces OPTIMIZE-1 Trial Update: Cohort Fully Dosed with No Adverse Effects Reported

LUND, Sweden, Jan. 18, 2022 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced an update on the on-going OPTIMIZE-1 clinical Phase Ib/II trial with the company's

Alligator Bioscience Announces OPTIMIZE-1 Trial Update: Cohort Fully Dosed with No Adverse Effects Reported - Vimarsana News

Alligator Bioscience Announces OPTIMIZE-1 Trial Update: Cohort Fully Dosed with No Adverse Effects Reported

/PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced an update on the on-going OPTIMIZE-1 clinical Phase Ib/II trial with the...

Alligator Bioscience Announces OPTIMIZE-1 Trial Update: Cohort Fully Dosed with No Adverse Effects Reported - Vimarsana News

Alligator Bioscience Announces OPTIMIZE-1 Trial Update: Cohort Fully Dosed with No Adverse Effects Reported

/PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced an update on the on-going OPTIMIZE-1 clinical Phase Ib/II trial with the...

Alligator Bioscience Announces Trial Update and Early Readout for ATOR-1017 Confirming Biomarker, Safety & Tolerability Data - Vimarsana News

Alligator Bioscience Announces Trial Update and Early Readout for ATOR-1017 Confirming Biomarker, Safety & Tolerability Data

/PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced an update on the on-going clinical Phase I trial with the 4-1BB (CD137) drug...